New drug MB0151 aims to shrink Hard-to-Treat cancers

NCT ID NCT06840821

First seen Jan 06, 2026 · Last updated May 10, 2026 · Updated 15 times

Summary

This study tests a new drug called MB0151 in adults with advanced solid tumors, including certain lung, breast, and neuroendocrine cancers that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors or slow their growth. Participants receive the drug by IV every two weeks, and the study will monitor side effects and anti-cancer activity.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cancer Hospital Affiliated to Shandong First Medical University

    RECRUITING

    Jinan, Shandong, 250117, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.